This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita HealthCare (DVA) Stock Moves -1.39%: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $82.03 in the latest trading session, marking a -1.39% move from the prior day.
DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $79.47, moving +0.61% from the previous trading session.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects fiscal 2020 revenue growth to be driven by recent product launches.
Top Ranked Growth Stocks to Buy for January 3rd
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 3rd.
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Top Ranked Growth Stocks to Buy for December 30th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 30th.
Top Ranked Growth Stocks to Buy for December 27th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 27th
Rosy Outlook for Outpatient and Home Healthcare Industry
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and participation in APM.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Top Ranked Growth Stocks to Buy for December 24th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 24th
U.S. Consumer Spending Bolsters Economic Growth: 5 Picks
by Zacks Equity Research
U.S. Consumer spending rises in November and with consumer sentiments' higher in December, these five stocks are a good buy.
DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $73.75, moving +0.41% from the previous trading session.
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
5 Healthcare Stocks to Keep the Winning Streak Alive in 2020
by Sapna Bagaria
Increasing incidence of chronic diseases, aging U.S. population, innovation and consolidation will drive the healthcare industry's growth in 2020.
Top Ranked Growth Stocks to Buy for December 17th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 17th
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Why Is DaVita HealthCare (DVA) Up 2.9% Since Last Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Option Care Health (BIOS) Surges: Stock Moves 7.3% Higher
by Zacks Equity Research
Option Care Health (BIOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Top Ranked Growth Stocks to Buy for December 5th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 5th:
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Samsung, Target and Davita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Samsung, Target and Davita